MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-14-2023
Zynerba Pharmaceuticals Deferred Revenue 2011-2026 | ZYNE
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Zynerba Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 172 K | 834 K | 841 K | 1.12 M | 1.04 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 M | 172 K | 802 K |
Quarterly Deferred Revenue Zynerba Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 172 K | - | 172 K | 172 K | 834 K | 834 K | 834 K | 834 K | 834 K | 834 K | 834 K | 841 K | 841 K | 841 K | 841 K | 1.12 M | 1.12 M | 1.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 M | 172 K | 769 K |
Deferred Revenue of other stocks in the Drug manufacturers industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aurora Cannabis
ACB
|
27 M | $ 3.51 | 1.73 % | $ 86.3 M |  Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
27.8 K | - | 0.86 % | $ 117 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
85.4 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
49 K | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
200 K | $ 12.0 | 1.95 % | $ 76.8 M | USA |
 |
DURECT Corporation
DRRX
|
545 K | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
114 K | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
11.5 M | $ 4.92 | -2.48 % | $ 317 M | USA |
 |
HEXO Corp.
HEXO
|
8.21 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Catalent
CTLT
|
250 M | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
207 K | $ 3.04 | -0.65 % | $ 42.7 M | USA |
 |
Athenex
ATNX
|
2.82 M | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
600 K | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
788 K | $ 34.83 | -0.23 % | $ 1.28 B | USA |
 |
Emergent BioSolutions
EBS
|
27.2 M | $ 8.15 | -1.98 % | $ 417 M | USA |
 |
Pacira BioSciences
PCRX
|
102 K | $ 21.89 | -3.53 % | $ 1.01 B | USA |
 |
China Pharma Holdings
CPHI
|
162 K | $ 0.64 | 3.23 % | $ 11.2 M |  China |
 |
ProPhase Labs
PRPH
|
2.5 M | - | - | $ 5.07 M | USA |
 |
TherapeuticsMD
TXMD
|
523 K | $ 2.3 | 5.99 % | $ 24 M | USA |
 |
Radius Health
RDUS
|
1 M | - | - | $ 1.42 B | USA |
 |
Veru
VERU
|
400 K | $ 2.4 | 1.27 % | $ 324 M | USA |
 |
Perrigo Company plc
PRGO
|
122 M | $ 10.19 | 4.84 % | $ 1.41 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
641 K | $ 2.47 | 2.49 % | $ 3.07 M | USA |
 |
Rockwell Medical
RMTI
|
46 K | $ 1.01 | 5.74 % | $ 23.6 M | USA |
 |
OptiNose
OPTN
|
160 K | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
235 K | $ 0.91 | 0.86 % | $ 45.4 M | USA |
 |
Recro Pharma
REPH
|
543 K | - | -4.76 % | $ 65.3 M | USA |
 |
Solid Biosciences
SLDB
|
10.4 M | $ 7.81 | 4.41 % | $ 319 M | USA |
 |
Tilray
TLRY
|
23.7 M | $ 6.9 | -0.07 % | $ 4.26 B | Canada |
 |
cbdMD
YCBD
|
503 K | $ 0.76 | 5.29 % | $ 3.28 M | USA |
 |
Zomedica Corp.
ZOM
|
368 K | - | -0.21 % | $ 98 M | USA |